News
-
-
-
-
PRESS RELEASE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH reaffirms Buy recommendation for Formycon AG and lowers price target to €80 amid expected launch of lucrative biosimilar FYB202. Analyst Simon Scholes provides insights on Formycon's future prospects and market dynamics -
-
-
PRESS RELEASE
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
Formycon initiates clinical program for FYB206, a biosimilar candidate for Keytruda, targeting immuno-oncology. Phase I and III trials underway to assess safety, efficacy, and PK equivalence -
-
-
PRESS RELEASE
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Formycon AG partners with MS Pharma for commercializing FYB203, a biosimilar candidate to Eylea in the MENA region, strengthening biosimilar portfolio and local production